An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants

Archive ouverte

Caillard, Sophie | Anglicheau, Dany | Matignon, Marie | Dürrbach, Antoine | Greze, Clarisse | Frimat, Luc | Thaunat, Olivier | Legris, Tristan | Moal, Valérie | Westeel, Pierre François | Kamar, Nassim | Gatault, Philippe | Snanoudj, Renaud | Sicard, Antoine | Bertrand, Dominique | Colosio, Charlotte | Couzi, Lionel | Chemouny, Jonathan Maurice, M | Masset, Christophe | Blancho, Gilles | Bamoulid, Jamal | Duveau, Agnès | Bouvier, Nicolas | Chavarot, Nathalie | Grimbert, Philippe | Moulin, Bruno | Le Meur, Yannick | Hazzan, Marc | Le Quintrec, Moglie

Edité par CCSD ; Nature Publishing Group -

International audience. Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. The aim of this registry-based observational study was to explore characteristics and clinical outcomes of recipients of kidney transplants included in the French nationwide Registry of Solid Organ Transplant Recipients with Covid-19. Covid-19 was diagnosed in symptomatic patients who had a positive PCR assay for SARS-CoV-2 or having typical lung lesions on imaging. Clinical and laboratory characteristics, management of immunosuppression, treatment for Covid-19, and clinical outcomes (hospitalization, admission to intensive care unit, mechanical ventilation, or death) were recorded. Risk factors for severe disease or death were determined. Of the 279 patients, 243 were admitted to hospital and 36 were managed at home. The median age of hospitalized patients was 61.6 years; most had comorbidities (hypertension, 90.1%; overweight, 63.8%; diabetes, 41.3%; cardiovascular disease, 36.2%). Fever, cough, dyspnea, and diarrhea were the most common symptoms on admission. Laboratory findings revealed mild inflammation frequently accompanied by lymphopenia. Immunosuppressive drugs were generally withdrawn (calcineurin inhibitors 28.7%; antimetabolites 70.8%). Treatment was mainly based on hydroxychloroquine (24.7%), antiviral drugs (7.8%), and tocilizumab (5.3%). Severe Covid-19 occurred in 106 patients (46%). Forty-three hospitalized patients died (30-day mortality 22.8%). Multivariable analysis identified overweight, fever, and dyspnea as independent risk factors for severe disease, whereas age over 60 years, cardiovascular disease, and dyspnea were independently associated with mortality. Thus, Covid-19 in recipients of kidney transplants portends a high mortality rate. Proper management of immunosuppression and tailored treatment of this population remain challenging.

Suggestions

Du même auteur

Clinical utility of biochemical markers for the prediction of COVID-19-related mortality in kidney transplant recipients

Archive ouverte | Caillard, Sophie | CCSD

International audience

Is COVID‐19 infection more severe in kidney transplant recipients?

Archive ouverte | Caillard, Sophie | CCSD

International audience. There are no studies which have compared the risk of severe COVID-19 and related mortality between transplant recipients and nontransplant patients. We enrolled two groups of patients hospita...

Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients

Archive ouverte | Berger, Bastien | CCSD

International audience. Introduction - SARS-CoV-2 pandemic evolved in 2 consecutive waves during 2020. Improvements in the management of COVID-19 led to a reduction in mortality rates among hospitalized patients dur...

Chargement des enrichissements...